Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : OPKO Health Get FDA Extension for Review of Somatrogon Biologics License Application

09/24/2021 | 04:37pm EDT


ę MT Newswires 2021
All news about PFIZER, INC.
05:23pPFIZER : States can reserve COVID-19 shots for younger kids next week
AQ
02:55pFDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
02:13pMODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
RE
01:40pPFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
AQ
01:11pMODERNA : U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ
RE
01:02pPFIZER : FDA panel takes up tough questions on J&J COVID-19 boosters
AQ
11:51aMODERNA : U.S. FDA advisers to vote on J&J COVID-19 vaccine booster
RE
11:07aTHE LATEST : Pfizer seeks European OK for child vaccines
AQ
11:02aPFIZER : BioNTech ask EU agency to OK vaccine for kids 5-11
AQ
10:55aPFIZER : BioNTech Makes European Medicines Agency Submission of Data Focusing COVID-19 Vac..
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 101 M - -
Net income 2021 18 457 M - -
Net Debt 2021 29 308 M - -
P/E ratio 2021 12,3x
Yield 2021 3,79%
Capitalization 234 B 234 B -
EV / Sales 2021 3,24x
EV / Sales 2022 3,70x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 41,67 $
Average target price 45,72 $
Spread / Average Target 9,72%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.12.52%233 631
JOHNSON & JOHNSON1.73%421 487
ROCHE HOLDING AG15.58%336 383
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.19%214 579
MERCK & CO., INC.-4.24%198 283